Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 21.
doi: 10.1038/s41581-025-00980-z. Online ahead of print.

Antigens in membranous nephropathy: discovery and clinical implications

Affiliations
Review

Antigens in membranous nephropathy: discovery and clinical implications

Sanjeev Sethi et al. Nat Rev Nephrol. .

Abstract

Membranous nephropathy is an autoimmune disease that results in an accumulation of antigen-antibody (IgG) immune complexes along the subepithelial region of the glomerular basement membrane and is the most common cause of nephrotic syndrome in adults. The diagnosis of membranous nephropathy is based on the presence of granular IgG on immunofluorescence microscopy and subepithelial electron dense deposits along the glomerular basement membrane on electron microscopy. Prior to 2009, the target antigen within the immune complexes was unknown. However, in the past 15 years, and in particular the past 5 years, several target antigens have been identified. These target antigens include PLA2R, THSD7A, EXT1 and EXT2, NELL1, SEMA3B, NCAM1, CNTN1, HTRA1, FAT1, PCDH7, NTNG1, PCSK6, NDNF and MPO. Several rare putative antigens have also been reported. These findings have transformed our understanding of membranous nephropathy from that of an idiopathic disease, which results from an autoimmune response to an unknown target antigen, to a disease in which a target antigen can be identified in ~80% of cases. Improved understanding of the distinctive clinical association, pathology and prognostic findings of each target antigen will have implications for clinical evaluation and therapeutic targeting in patients with membranous nephropathy.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

Similar articles

References

    1. Couser, W. G. Primary membranous nephropathy. Clin. J. Am. Soc. Nephrol. 12, 983–997 (2017). - PubMed - PMC
    1. Ronco, P. et al. Membranous nephropathy. Nat. Rev. Dis. Primers 7, 69 (2021). - PubMed
    1. Sethi, S. et al. Mayo clinic consensus report on membranous nephropathy: proposal for a novel classification. Kidney Int. 104, 1092–1102 (2023). - PubMed
    1. Beck, L. H. et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361, 11–21 (2009). - PubMed - PMC
    1. Tomas, N. M. et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N. Engl. J. Med. 371, 2277–2287 (2014). - PubMed - PMC

LinkOut - more resources